Zobrazeno 1 - 10
of 4 385
pro vyhledávání: '"braf-mutation"'
Autor:
Daisuke Uno, Kazuhira Endo, Tomomi Yoshikawa, Nobuyuki Hirai, Eiji Kobayashi, Yosuke Nakanishi, Satoru Kondo, Tomokazu Yoshizaki
Publikováno v:
Thyroid Research, Vol 17, Iss 1, Pp 1-9 (2024)
Abstract Introduction Activation of the MAPK pathway by genetic mutations (such as BRAF and RET) initiates and accelerates the growth of papillary thyroid carcinoma (PTC). However, the correlation between genetic mutations and clinical features remai
Externí odkaz:
https://doaj.org/article/c9b65364cc504a00b68c1590d7d2b76e
Autor:
Justin Lee, BA, Sabitha Sasidharan Pillai, MD, Avani Ganta, MD, Chanika Phornphutkul, MD, Jose Bernardo Quintos, MD
Publikováno v:
AACE Clinical Case Reports, Vol 10, Iss 5, Pp 174-178 (2024)
Background/Objective: We present an adolescent male with Noonan syndrome (NS) and celiac disease (CD) who attained normal adult height with growth hormone (GH) treatment and gluten-free diet (GFD). Case Report: A 15 ½ year old healthy male presented
Externí odkaz:
https://doaj.org/article/c9e11aa527234ae7a6f1d43ebbe7f65c
Autor:
J. Steininger, C. Buszello, R. Oertel, M. Meinhardt, S. Schmid, K. Engellandt, S. Herold, S. Stasik, A. Ebrahimi, B. Renner, C. Thiede, I.Y. Eyüpoglu, G. Schackert, S. Beissert, F. Meier, J. Radke, D. Westphal, T. A. Juratli
Publikováno v:
Acta Neuropathologica Communications, Vol 12, Iss 1, Pp 1-12 (2024)
Abstract Epithelioid glioblastoma (eGB), a very aggressive and rare brain tumour, is associated with a dismal median overall survival. Effective therapies for patients with eGB, particularly with leptomeningeal dissemination, are still lacking. Here,
Externí odkaz:
https://doaj.org/article/0fb644eeacee4ed68b3f90f56d2e1371
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Non-small cell lung cancer (NSCLC) is one of the most common malignancies in the world. EGFR tyrosine inhibitors are the preferred first-line treatment for patients with epidermal growth factor-cell receptor mutant (EGFR mutant) advanced NSCLC. Unfor
Externí odkaz:
https://doaj.org/article/c240e7fda61541daa0fbe059229966dc
Autor:
Yanwei Chen, Shuangshuang Zhao, Zheng Zhang, Zheming Chen, Bingxin Jiang, Maohui An, Mengyuan Shang, Xincai Wu, Xin Zhang, Baoding Chen
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
PurposePapillary thyroid carcinoma (PTC) frequently coexists with Hashimoto’s thyroiditis (HT), which poses challenges in detecting central lymph node metastasis (CLNM) and determining optimal surgical management. Our study aimed to identify the in
Externí odkaz:
https://doaj.org/article/5c3a00a9c5134b168b47ee47c9943ba0
Autor:
Fausto Petrelli, Maria Antista, Lorenzo Dottorini, Alessandro Russo, Marcella Arru, Roberta Invernizzi, Mariangela Manzoni, Chiara Cremolini, Alberto Zaniboni, Ornella Garrone, Gianluca Tomasello, Michele Ghidini
Publikováno v:
Heliyon, Vol 10, Iss 17, Pp e36497- (2024)
Introduction: The molecular profile of colorectal cancer (CRC) plays a crucial role in understanding patient prognosis and treatment response. Within CRC, a distinct subgroup can be identified by the presence of the BRAF V600E mutation. This specific
Externí odkaz:
https://doaj.org/article/4eb10c4254cd437fbfa1d55b7078f35a
Publikováno v:
Thoracic Cancer, Vol 15, Iss 18, Pp 1454-1456 (2024)
Abstract Although dabrafenib plus trametinib has been approved for BRAF V600E mutation positive advanced non‐small cell lung cancer (NSCLC), data on its efficacy against uncommon BRAF mutations are still limited due to their rare frequency. We repo
Externí odkaz:
https://doaj.org/article/8304f5f801794ef8a5a47c81e64fabd0
Autor:
Lovisa Falkman, Anders Sundin, Britt Skogseid, Johan Botling, Yvette Bernardo, Göran Wallin, Liang Zhang, Staffan Welin, Ieva Lase, Kazhan Mollazadegan, Joakim Crona
Publikováno v:
Upsala Journal of Medical Sciences, Vol 129, Pp 1-7 (2024)
Background: Metastatic neuroendocrine carcinoma (NEC) is associated with short survival. Other than platinum-based chemotherapy, there is no clear standard regimen. Current guidelines suggest that combination treatment with BRAF-inhibitors should be
Externí odkaz:
https://doaj.org/article/e138f2357a1d4fe5ade89d82ea78a815
Autor:
S. A. Yаrgunin, I. V. Reshetov, Ya. N. Shoykhet, S. I. Samoylova, O. Yu. Chukhrai, S. N. Pyatakov, V. S. Yаrgunin
Publikováno v:
Инновационная медицина Кубани, Vol 0, Iss 1, Pp 8-17 (2024)
Background: Cutaneous melanoma is an extremely aggressive disease with an unpredictable prognosis. Even among patients with similar tumor parameters and extent of surgical treatment, survival may vary. The extent of surgical resection of primary cuta
Externí odkaz:
https://doaj.org/article/2ed655b3f4d043a496a775181b29395b
Autor:
Anne Hansen Ree, Eirik Høye, Ying Esbensen, Ann-Christin R. Beitnes, Anne Negård, Linn Bernklev, Linn Kruse Tetlie, Åsmund A. Fretland, Hanne M. Hamre, Christian Kersten, Eva Hofsli, Marianne G. Guren, Halfdan Sorbye, Hilde L. Nilsen, Kjersti Flatmark, Sebastian Meltzer
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
The randomized METIMMOX trial (NCT03388190) examined if patients with previously untreated, unresectable abdominal metastases from microsatellite-stable (MSS) colorectal cancer (CRC) might benefit from potentially immunogenic, short-course oxaliplati
Externí odkaz:
https://doaj.org/article/a08572504c1241d5a365f6b0a359ede1